AURA
Aura Biosciences, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$6.14Close
$390.4MMarket cap
$4.97 – $8.9052-week range
Nov 5, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 33 · weaker than 67% of stocks over 12 months
- Far from its high 31% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
31%
1wk
down 2.5%
price change
1mo
down 2.2%
price change
12-month return
up 1%
market up 11% ·
its own down 11%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.9×
price / book
Earnings yield
down 34.1%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 74%
return on equity
Free cash margin
—
-$85.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.7%
$0.29 a day · 2×ATR $5.56
RS
33 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.68
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 27.2% over the year, from 50m to 64m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026+1% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$22.2M | -$35.2M | -$60.3M | -$85.0M | -$96.1M | -$112.8M |
| Net income | -$22.2M | -$35.3M | -$58.8M | -$76.4M | -$86.9M | -$106.2M |
| Earnings per share | — | -$6.83 | -$1.96 | -$1.93 | -$1.75 | -$1.76 |
| Free cash flow | -$25.1M | -$34.5M | -$55.7M | -$64.6M | -$81.1M | -$85.2M |
| Cash | $17.4M | $149.1M | $121.6M | $41.1M | $31.7M | $59.5M |
| Shareholders' equity | -$108.7M | $152.3M | $195.6M | $225.8M | $152.0M | $136.9M |
| Shares outstanding | 381.12k | 29.21m | 37.77m | 49.35m | 50m | 63.59m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Mar 30, 2026 | Annual ↗ | Dec 31, 2025 | 89d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 15, 2025 | Quarterly ↗ | Mar 31, 2025 | 45d |
| Mar 24, 2025 | Annual ↗ | Dec 31, 2024 | 83d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 27, 2024 | Annual ↗ | Dec 31, 2023 | 87d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 11, 2026 | Results · Restructuring · Director or officer change · Other events ↗ |
| Aug 5, 2026 | Shareholder vote ↗ |
| Jul 8, 2026 | Director or officer change ↗ |
| Jun 11, 2026 | Shareholder vote ↗ |
| May 11, 2026 | Results · Other events ↗ |
| May 5, 2026 | Material agreement ↗ |
| May 4, 2026 | Material agreement · Results · Other events ↗ |
| May 4, 2026 | Director or officer change · Regulation FD · Other events ↗ |
| Mar 30, 2026 | Results · Other events ↗ |
| Nov 13, 2025 | Results · Other events ↗ |
| Aug 13, 2025 | Results · Other events ↗ |
| Jun 18, 2025 | Shareholder vote ↗ |